SS
HRTX icon

SBI Securities’s Heron Therapeutics HRTX Stock Holding History

SBI Securities’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3 Buy
6
+5
+500% +$4 ﹤0.01% 4020
2026
Q1 		$1 Hold
1
– – ﹤0.01% 3982
2025
Q4 		$1 Hold
1
– – ﹤0.01% 3998
2025
Q3 		$1 Sell
1
-1
-50% -$2 ﹤0.01% 4171
2025
Q2 		$4 Hold
2
– – ﹤0.01% 4077
2025
Q1 		$4 Sell
2
-12,602
-100% -$24.5K ﹤0.01% 4043
2024
Q4 		$19.3K Buy
+12,604
New +$20.4K ﹤0.01% 1373

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

SBI Securities's HRTX Position: Q2 2026 in Review

SBI Securities increased its Heron Therapeutics (HRTX) stake by 500% in Q2 2026, buying an estimated $4 and bringing the position to 6 shares worth $3. The position accounts for ﹤0.01% of the portfolio, ranked #4020.

SBI Securities first reported a position in HRTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $19.3K in Q4 2024. 162 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • SBI Securities held 6 shares of Heron Therapeutics worth $3 as of Q2 2026.
  • SBI Securities bought 5 Heron Therapeutics shares in Q2 2026, an estimated $4.
  • Heron Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #4020 holding.
  • SBI Securities first reported a position in Heron Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Heron Therapeutics position peaked at $19.3K in Q4 2024.
  • 162 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.